Elexacaftor-tezacaftor-ivacaftor (ETI) has demonstrated lung function benefit in clinical trials for people with cystic fibrosis. However, evidence is limited on how ETI affects within-person lung function trajectories over longer periods (>1 year) and whether initial improvements are sustained. This study aimed to estimate age-adjusted lung clearance index (LCI) trajectories before and after ETI initiation in children aged 3–17 years, quantify acute LCI changes at ETI start, and evaluate whether LCI stability changed up to three years after starting ETI.
This was a prospective observational study conducted at a tertiary hospital. Inclusion criteria for trajectory analysis required children aged 3–17 years to have at least two LCI testing occasions both before and after ETI initiation. For assessment of acute change after ETI initiation, children with at least one pre-ETI and one post-ETI LCI occasion were included. The authors report cohort sample sizes for specific analyses where applicable.
Lung function was assessed using the lung clearance index (LCI), a multiple-breath washout measure sensitive to ventilation inhomogeneity. Age-adjusted LCI trajectories were estimated separately for the time periods before and after ETI initiation using linear mixed-effects models to account for repeated measures within individuals. Paired Wilcoxon tests were used to compare pre- and post-ETI LCI values when appropriate. Trajectory estimates are presented as mean change in LCI (turnovers per year) with 95% confidence intervals and sample size denominators as reported.
The mean longitudinal change in LCI before ETI initiation was reported as −0.007 turnovers per year (95% CI −0.28 to 0.27; n=35). After ETI initiation, the mean longitudinal change was 0.12 turnovers per year (95% CI −0.17 to 0.41; n=20). These trajectory estimates indicate that, on average, there was not a large progressive decline in LCI prior to ETI and that post-ETI trajectories demonstrated maintained stability rather than a marked additional decline or improvement in slope over time.
Acute within-individual comparisons of LCI before versus after ETI initiation showed a median LCI difference of −0.70 turnovers (95% CI −0.84 to −0.46), with p<0.001 by paired Wilcoxon test, indicating a statistically significant immediate improvement in ventilation homogeneity after starting ETI.
Using an LCI threshold of ≥7.1 turnovers to indicate impaired lung function, the proportion of children meeting or exceeding that threshold decreased from 57% (30 of 53 patients) before ETI to 26% (14 of 53 patients) after ETI initiation. This shift reflects a clinically relevant reduction in the number of children with impaired LCI following treatment.
The authors report that within-individual variability in LCI measurements decreased after starting ETI. Reduced measurement variability suggests greater stability of lung function post-therapy and supports the consistency of observed improvements in LCI across repeated measurements up to three years after ETI initiation.
In this real-world longitudinal cohort of children with cystic fibrosis, initiation of elexacaftor-tezacaftor-ivacaftor was associated with an acute and statistically significant improvement in LCI and a reduced prevalence of impaired LCI (≥7.1 turnovers). Trajectory analyses showed maintained stability of LCI following ETI initiation rather than ongoing deterioration, and within-individual LCI variability declined post-treatment. Collectively, these findings provide longitudinal evidence that ETI confers both immediate improvement and sustained stabilization of ventilation inhomogeneity as measured by LCI in children aged 3–17 years, with observations reported up to three years after initiation.
The study was approved by Children's Health Queensland Human Research Ethics Committee (HREC/19/QCHC/51727). The authors declare that CW disclosed competing interests in the uploaded ICMJE form; other authors reported no competing interests. Funding was declared from the Cystic Fibrosis Foundation (USA), Children's Hospital Foundation, and the National Health and Medical Research Council (grant 1193840). The authors note that data from the study are available on reasonable request. Specific participant counts and additional methodological details are those reported in the source article.